Preview

Current Pediatrics

Advanced search

USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN PROPHYLAXIS OF SEVERE ANEMIA IN PREMATURELY BORN INFANTS WITH VERY LOW AND EXTREMELY LOW BODY WEIGHT

Abstract

Problem of prophylaxis and treatment of early anemia of prematurely born infants is still very important. It's related to increase of rate of infants, surviving with very low and extremely low body weight at the time of birth. The purpose of trial was to provide an optimization of scheme of treatment of early anemia with recombinant human erythropoietin (rh-EPO, Recormon). This trial included 94 infants with very low and extremely low body weight at the time if birth. 26 infants was treated with rh-EPO 500 ME/kg once a week, and 33 infants — with rh-EPO 1000 ME/kg once a week, 35 infants was in control group. Rh-EPO was administrated by subcutaneous introduction once a week, from 3–5 day of life during 6 week. All patients receive iron in dose 4 mg/kg daily. As a result, the need in transfusion was decreased 5 times lower in group of children receiving rh-EPO 500 ME/kg weekly compared to control group. Patients, receiving rh-EPO 1000 ME/kg weekly, had no need in hemotransfusions.
Key words: premature, early anemia, recombinant human erythropoietin, hemotransfusion.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(2):38-43)

About the Authors

Yu.N. Pilipenko
Ryazan Regional Children's Clinical Hospital
Russian Federation



A.V. Dmitriev
I.P. Pavlov Ryazan State Medical University
Russian Federation


V.G. Demikhov
Federal Scientific Clinical Center of Children's Hematology, Oncology and Immunology, Ryazan
Russian Federation




E.F. Morschakova
Federal Scientific Clinical Center of Children's Hematology, Oncology and Immunology, Ryazan
Russian Federation


References

1. Бисярина В.П., Казакова Л.Н. Железодефицитные анемии у детей раннего возраста. М.: Медицина. 1979. С. 179.

2. Дегтярев Д.Н., Куфмашева Н.А., Володин Н.Н. Современное представление о патогенезе и лечении анемии у недоношенных детей. Педиатрия. 1995; 2: 78–81.

3. Султанова Г.Ф. Анемия недоношенных детей. Чебоксары. 1989. С. 17–40, С. 82–89.

4. Морщакова Е.Ф., Павлов А.Д., Румянцев А.Г. Эритропоэз и его регуляция в эмбриональном, фетальном и неонатальном периодах. Российский вестник перинатологии и педиатрии. 1999; 44 (3): 12–16.

5. Румянцев А.Г. Морщакова Е.Ф., Павлов А.Д. Эритропоэтин. Биологические свойства. Возрастная регуляция эритропоэза. Клиническое применение. М. 2002. С. 137–144, С. 266–278.

6. Жетишев Р.А. Эритропоэтин: механизмы регуляции эритропоэза и применение рекомбинантного препарата в профилактике и лечении анемии у детей раннего возраста (обзор литературы). Российский семейный врач. 2000; 2: 12–16.

7. Мосягина Е.Н. Анемии детского возраста. М. 1969. 300 с.

8. Пясецкая Н.М. Paнняя анемия недоношенных детей: профилактика и лечение рекомбинантным эритропоэтином (эпоэтин-бета). Учебное пособие. Киев. 2004. 26 с.

9. Ohls R., Veerman M., Christensen R. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J. Pediatr. 1996; 128: 518–523.

10. Stockman J.A. Anaemia of prematurity. Current concepts in the issue of when to transfuse. Pediatric Clinic of North Am. 1986; 33: 111–128.

11. Testa M., Reali A., Copula M. Role of rHuEPO on blood transfusions in preterm infants after the fifteenthday of life. Pediatr Hematol Oncol. 1998; 5 (5): 415–420.

12. Аграненко В.А., Крижевская Ю.В. Передача вирусных инфекций при переливаниях крови и её компонентов. Гематология и трансфузиология. 1991; 6: 25–27.

13. Halperin D., Wacker P., Lacourt G. еt al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J. Pediatr. 1990; 116: 779–786.

14. Carbonell–Estrany X., Figuerqs–Alou J., Alvares E. Erythropoietin and prematurity – where do we stand? J. Perinat. Med. 2005; 33 (4): 277–286.

15. Homono S., Muqishima M., Minato M. Prediction of transfusions in extremely low-birthweight infants in the erythropoietin era. Department of Pediatrics. Nihon University School of Medicine. Tokyo. 2006; 48 (6): 572-576.

16. Badiee Z., Pourmirzaiee M., Kelishadi R. et al. Recombinant human erythropoietin and blood transfusion in low birth weight preterm infants under restrictive transfusion guidelines. Saudi Med. J. 2006; 27 (6): 817–820.

17. Warwood T., Ohls R. , Lambert D. et al. Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates. J. Perinatol. 2006; 26 (10): 636–639.

18. Klipp M., Holzwarth A.U., Poeschl J.M. et al. Effects of erythropoietin on erythrocyte deformability in non-transfused preterm infants. Acta Paediatr. 2007; 96 (2): 253–256.

19. Haiden N., Klebermass K., Cardona F. et al. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics. 2006; 118 (1): 180–188.


Review

For citations:


Pilipenko Yu., Dmitriev A., Demikhov V., Morschakova E. USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN PROPHYLAXIS OF SEVERE ANEMIA IN PREMATURELY BORN INFANTS WITH VERY LOW AND EXTREMELY LOW BODY WEIGHT. Current Pediatrics. 2009;8(2):38-43.

Views: 793


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)